

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS P.O. Box 1450 Alexandria, Vignin 22313-1450 www.uspto.gov

APPLICATION N	O. F	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/021,217		12/12/2001	Thomas Raschke	Beiersdorf 754-KGB	8909
27384	7590	05/20/2003			
	RISCOE		EXAMINER		
220 EAST	F 42ND STR	HLIN & MARCUS, I REET, 30TH FLOOR	WELLS, LAUREN Q		
NEW YORK, NY 10017				ART UNIT	PAPER NUMBER
				1617	(0
				DATE MAILED: 05/20/2003	V

Please find below and/or attached an Office communication concerning this application or proceeding.

•	()			()					
		Ap	Application No.		Applicant(s)				
Office Action Summary			10/021,217		RASCHKE ET AL.				
			Examiner		Art Unit				
		1	uren Q Wells		1617				
The MAILING DATE of P riod for Reply	of this commu	unication appears	on the cover she	et with the c	orrespondence ad	dress			
A SHORTENED STATUTO THE MAILING DATE OF TH - Extensions of time may be available after SIX (6) MONTHS from the mail If the period for reply specified above If NO period for reply is specified above Failure to reply within the set or exte Any reply received by the Office later earned patent term adjustment. See Status	HIS COMMU under the provision ing date of this core is less than thirty ove, the maximum nded period for reproduced than three month.	NICATION. ons of 37 CFR 1.136(a). mmunication. (30) days, a reply within statutory period will app ply wilt, by statute, caus- s after the mailing date	In no event, however, renthe statutory minimum oly and will expire SIX (6 e the application to become	may a reply be tin of thirty (30) day 3) MONTHS from ome ABANDONE	nely filed s will be considered timel the mailing date of this or D (35 U.S.C. § 133).				
1) Responsive to comm	nunication(s)	filed on <u>07 April</u>	<u>2003</u> .						
2a)⊠ This action is FINAL		2b)∏ This ac	ction is non-final.						
3) Since this application closed in accordance Disposition of Claims						e merits is			
4) Claim(s) 1-9 is/are pe	anding in the	application							
4a) Of the above claim	•	• •	om consideration	า					
5) Claim(s) is/are		are witherawir ii		••					
6)⊠ Claim(s) <u>1-9</u> is/are rej									
	Claim(s) is/are objected to.								
8) Claim(s) are su	•	riction and/or ele	ction requiremen	ıt.					
Application Papers	,								
9) The specification is ob	jected to by t	the Examiner.		•					
10) The drawing(s) filed or	n is/ar	e: a)⊡ accepted o	or b) objected to	by the Exa	miner.				
Applicant may not requ	-	-		•	• •				
11) The proposed drawing	correction fi	led on is:	a) approved b)∏ disappro	oved by the Examin	er.			
If approved, corrected	_								
12)☐ The oath or declaration	n is objected	to by the Examir	ner.						
Priority under 35 U.S.C. §§ 11	9 and 120								
13)⊠ Acknowledgment is m		- ,	ority under 35 U.S	S.C. § 119(a)-(d) or (f).				
a)⊠ All b)⊡ Some * c)☐ None of	:							
1. Certified copies	of the priori	ty documents ha	ve been received	l.					
_	of the priorit	ty documents ha	ve been received	l in Applicati	on No				
	from the Inte	rnational Bureau	(PCT Rule 17.2)	(a)).	ed in this Nationaled.	Stage			
14) Acknowledgment is ma			•			l application).			
a) ☐ The translation of 15)☐ Acknowledgment is ma	the foreign l	anguage provisio	onal application h	as been rec	eived.	•			
Attachment(s)	=: =:= ****		,	33					
Notice of References Cited (PTO 2) Notice of Draftsperson's Patent E 3) Information Disclosure Statemen	Drawing Review	·	5) 🔲 Noti	ce of Informal I	v (PTO-413) Paper No Patent Application (PT				

Art Unit: 1617

DETAILED ACTION

Claims 1-9 are pending. The Amendment filed 4/7/03, Paper No. 7, added claim 9.

The Arguments filed 4/7/03, Paper No. 7, to the 35 USC 103 rejection in the previous Office Action are not persuasive to overcome the rejection. See below for details.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 1-9 are rejected under 35 U.S.C. 103(a) as being unpatentable over WO 99/37282. See US 6,503,518, which is an English language equivalent of WO 99/37282, for citation purposes.

The instant invention is directed toward a combination of one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid and alpha-lipoic acid. The instant invention is further directed to applying such a composition to the skin.

US 581 is directed to cosmetic and dermatological compositions that comprise one or more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid (abstract). US '518 discloses at column 4, lines 51-53 that the compositions preferably contain antioxidants. Lipoic acid is disclosed as a suitable antioxidant at column 4, lines 58-65. For glyceryl stearate citrate as a partially neutralized ester of monoglycerides and/or diglycerides of saturated fatty acids with citric acid within the instant claimed concentration

Art Unit: 1617

ranges and oil-in-water emulsions see the examples beginning at column 8. See also claims 1 and 2. For lotions and creams see col. 6, lines 34-41. For gels see col. 10, line 54.

US '518 does not explicity teach one composition comprising both one ore more partially neutralized esters of monoglycerides and/or diglycerides of saturated fatty acids with citric acid and alpha-lipoic acid or application to the skin.

US '518 does disclose that lipoic acid can be added to the composition for it's antioxidant properties. Nothing unobvious is seen in substituting the known claimed isomer for the compound of US '518 since such structurally related compounds suggest one another and would be expected to share common properties absent a showing of unexpected results. It is well-known and common practice to apply cosmetic and dermatological compositions to the skin. Therefore, application of the composition to the skin as instantly claimed in not considered patentable over the prior art.

It would have been obvious to one of ordinary skill in the art at the time the invention was made to prepare the composition of US '518 using any isomer of lipoic acid and apply it to the skin expecting to obtain a cosmetic and dermatological composition with antioxidant properties.

Response to Arguments

Applicant argues, "The principle of In re Baird is relevant to this matter. Baird cautions against finding a specific claimed combination obvious, when it is merely suggested by a reference's shotgun disclosure of the entire art. The entirety of the reference(s) must suggest the claimed combination. Thus, as in von der Fecht, merely listing a component compound, without more, is not sufficient to establish prima facie case of obviousness. von der Fecht's

Art Unit: 1617

large number of antioxidants disclosed in the reference does not constitute sufficient suggestion for specifically selected lipoic acid for the claimed composition against a back group of hundreds of antioxidants". This argument is not persuasive. The Examiner respectfully points out that von der Fecht is not directed to a shotgun disclosure of the entire art of antioxidants. Von der Fecht broadly teaches that any known antioxidant can be utilized in his composition and then specifically teaches antioxidants that are preferably combined with his composition.

Furthermore, in Col. 5, lines 33-34, von der Fecht specifically teaches that "For the purposes of the present invention, oil-soluble antioxidants can be used particularly advantageously", wherein lipoic acid is oil-soluble. Thus, the von der Fecht provides motivation teach lipoic acid as the antioxidant.

Regarding Applicant's arguments in reference to Merck v. Biocraft, the Examiner respectfully points out that Applicant has not provided any unexpected results. Thus, this argument is moot.

Applicant argues, "von der Fecht clearly states that antioxidants are unnecessary in using its composition". This argument is not persuasive. The Examiner respectfully points out that it is well-established that consideration of a reference is not limited to the preferred embodiments or working examples, but extends to the entire disclosure for what it fairly teaches, when viewed in light of the admitted knowledge in the art, to person of ordinary skill in the art. In re Boe, 355 F.2d 961, 148 USPQ 507, 510 (CCPA 1966); In re Lamberti, 545 F.2d 747, 750, 192 USPQ 279, 280 (CCPA 1976); In re Fracalossi, 681 F.2d 792, 794, 215 USPQ 569, 570 (CCPA 1982); In re Kaslow, 707 F.2d 1366, 1374, 217 USPQ 1089, 1095 (Fed. Cir. 1983). Furthermore, the

Art Unit: 1617

Examiner respectfully points out that all of the examples of von der Fecht exemplify antioxidants.

Applicant argues, "Von der Fecht discloses a clear preference for distinct antioxidants". This argument is not persuasive. As stated above, the Examiner respectfully points out that the consideration of a reference is not limited to its preferred embodiments.

Conclusion

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lauren Q Wells whose telephone number is (703) 305-1878. The examiner can normally be reached on M-F (7-5:30), with alternate Mondays off.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on (703)305-1877. The fax phone numbers for

Art Unit: 1617

Page 6

the organization where this application or proceeding is assigned are (703) 872-9306 for regular communications and (703) 872-9307 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

lqw May 6, 2003

> SREENI PADMANABHAN PRIMARY EXAMINER